Tyurin, A.V.,
Salimgareeva, M.K.,
Miniakhmetov, I.R.,
Khusainova, R.I.,
Samorodov, A.,
Pavlov, V.N.,
Kzhyshkowska, J. (2022) -lymphocytes, T-cytotoxic, T-
activated and B-lymphocytes correlated with the higher
levels of CRP. The absolute
-crown-6 ether in toluene. In vitro anticoagulant and antiplatelet
activity of the adduct was studied
KHALIULLIN, F.A.,
KLEN, E.E.,
PAVLOV, V.N.,
SAMORODOV, A.V.,
SHEPILOVA, S.O.,
MAKAROVA, N.N.,
NURLANOVA, S.N.,
ABZALILOV, T.N. (2022)
studies of the antiplatelet, anticoagulant, and antioxidant
activity revealed promising compounds
Chen, P.,
Yu, Y.,
Su, S.,
Du, Z.,
Cai, B.,
Sun, X.,
Chattipakorn, N.,
Samorodov, A.V.,
Pavlov, V.N.,
Tang, Q.,
Cho, W.-J.,
Liang, G. (2023) ) derivatives and evaluated their anti-inflammatory
activities by measuring the release of cytokines
Khaliullin, F.A.,
Klen, E.E.,
Nikitina, I.L.,
Pavlov, V.N.,
Rozit, G.A.,
Gaisina, G.G.,
Samorodov, A.V. (2023) . An in vivo study of the antidepressant
activity revealed the promising compound 1-(1,1-dioxidothietan-3-yl)-4
Klen, E.E.,
Nikitina, I.L.,
Khaliullin, F.A.,
Shepilova, S.O.,
Nikitina, E.A.,
Gaisina, G.G.,
Samorodov, A.V.,
Pavlov, V.N. (2024) bioavailability. The compounds exhibited varying degrees of antidepressant
activity after a single intraperitoneal
Khaliullin, F. A.,
Klen, E. E.,
Nikitina, I. L.,
Pavlov, V. N.,
Rozit, G. A.,
Gaisina, G. G.,
Samorodov, A. V. (2023) . An in vivo
study of the antidepressant
activity revealed the promising compound 1-(1,1-dioxidothietan-3-yl)-4
Qian, J.,
Zhuang, F.,
Chen, Y.,
Fan, X.,
Wang, J.,
Wang, Z.,
Wang, Y.,
Xu, M.,
Samorodov, A.V.,
Pavlov, V.N.,
Liang, G. (2022) under high glucose condition, which was mediated by p38MAPK
activation. MD2 knockout or pharmacological